Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
作者信息
Seitter Samantha J, McClelland Paul H, Ahlman Mark A, Goff Stephanie L, Yang James C, McIntyre Lori, Rosenberg Steven A, Kochenderfer James N, Brudno Jennifer N
机构信息
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
出版信息
Leuk Lymphoma. 2022 Oct;63(10):2469-2473. doi: 10.1080/10428194.2022.2076853. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
Leuk Lymphoma. 2022 Oct;63(10):2469-2473. doi: 10.1080/10428194.2022.2076853. Epub 2022 Jun 9.
2
CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease.
Leuk Lymphoma. 2022 Oct;63(10):2263-2264. doi: 10.1080/10428194.2022.2102625. Epub 2022 Jul 20.
3
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022.
4
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Blood Adv. 2022 Feb 8;6(3):717-730. doi: 10.1182/bloodadvances.2021004557.
5
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
Blood Cancer J. 2023 May 3;13(1):66. doi: 10.1038/s41408-023-00837-3.
6
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
BMC Cancer. 2022 Apr 12;22(1):393. doi: 10.1186/s12885-022-09489-1.
7
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Eur J Haematol. 2024 Jan;112(1):51-63. doi: 10.1111/ejh.14132.
8
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1575-1582. doi: 10.1007/s00432-020-03198-7. Epub 2020 Mar 28.
9
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Blood. 2022 Aug 4;140(5):451-463. doi: 10.1182/blood.2022015795.
10
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma.
Front Immunol. 2024 Dec 9;15:1497736. doi: 10.3389/fimmu.2024.1497736. eCollection 2024.
引用本文的文献
1
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.
Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615-0.
2
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
Mol Ther Methods Clin Dev. 2024 Feb 13;32(1):101212. doi: 10.1016/j.omtm.2024.101212. eCollection 2024 Mar 14.
3
Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Front Immunol. 2023 Nov 27;14:1285406. doi: 10.3389/fimmu.2023.1285406. eCollection 2023.
4
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
J Pers Med. 2023 Nov 10;13(11):1595. doi: 10.3390/jpm13111595.
5
Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma.
Med Sci (Basel). 2023 Oct 12;11(4):67. doi: 10.3390/medsci11040067.
本文引用的文献
1
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Blood Adv. 2022 Feb 8;6(3):717-730. doi: 10.1182/bloodadvances.2021004557.
2
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cell Transplant. 2021 Jan-Dec;30:963689721996649. doi: 10.1177/0963689721996649.
3
CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.
Cancer Immunol Immunother. 2021 Aug;70(8):2379-2384. doi: 10.1007/s00262-021-02850-6. Epub 2021 Jan 18.
4
The treatment of Burkitt lymphoma in adults.
Blood. 2021 Feb 11;137(6):743-750. doi: 10.1182/blood.2019004099.
5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
6
Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.
Blood. 2020 Jun 25;135(26):2425-2427. doi: 10.1182/blood.2019002008.
7
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
J Cancer Res Clin Oncol. 2020 Jun;146(6):1575-1582. doi: 10.1007/s00432-020-03198-7. Epub 2020 Mar 28.
8
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20.
9
Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.
N Engl J Med. 2019 Apr 18;380(16):1586. doi: 10.1056/NEJMc1901464.
10
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
Zotero 插件